Thu 20 Aug 2026
All official websites of government entities in the Kingdom of Saudi Arabia end with.gov.sa.
Ensure the website is using the HTTPS protocol.
Registered with the Digital Government Authority under number:
| Study Title | Study Sponsor | Status | Study Drug | Trial Phase | Study Protocol Number | Site |
|---|---|---|---|---|---|---|
| A PARTIALLY DOUBLE-BLINDED, RANDOMIZED, CONTROLLED, PLACEBO-CONTROLLED STUDY, A PHASE III TRIAL OF SAFETY AND EFFICACY OF PREMEDICATION WITH DEXMEDETOMIDINE AND MIDAZOLAM IN PEDIATRIC PATIENTS | King Faisal Specialist Hospital and Research Centre | Ongoing | DEXMEDETOMIDINE | 3 | RAC# 21901310 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| "A Non-Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched and HLA-Matched Bone Marrow for Patients with Sickle Cell Disease and Other Hemoglobinopathies " | KAIMRC | Ongoing | HYDROXYUREA (HYDROXYCARBAMIDE) | 3 | CT20/008/R | King Abdulaziz Medical City NG (Riyadh) |
| A National Collaborative Multicenter Phase II Study for Potential Efficacy of Convalescent Plasma to Treat Severe COVID-19 and Patients at High Risk of Developing Severe COVID-19 | GDRS (MOH) | Ongoing | Convalescent Plasma | 2 | 20-COVID-19-01M | KFSH-D |
| A multinational, open-label, randomised, controlled trial to investigate efficacy and safety of NNC0365-3769 (Mim8) in adults and adolescents with haemophilia A with or without inhibitors. | Novo Nordisk | Ongoing | Mim8 | 3 | NN7769-4514 | King Faisal Specialist Hospital and Research Center (Riyadh) |
| "A Multinational, Open Label, Randomized, Active-controlled, 3-arm Parallel Group, 24-week Study Comparing the Combination of Glimepiride and Metformin Versus Glimepiride and Metformin Alone in Patients With Type 2 Diabetes " | Sanofi | Terminated | GLIMEPIRIDE-HOE490 | 3 | GLIME_R_05809 | KFSH |
| A Multicentre, Randomized, Double-Blind, Placebo Controlled, Parallel Group, Phase 3 Study to Evaluate the Efficacy and Safety of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma (NAVIGATOR) | AstraZeneca | Completed | Tezepelumab | 3 | D5180C00007 | KAUH-J |
| A Multicentre, Double-blind, Randomized, Placebo Controlled, Parallel Group, Phase 3, Safety Extension Study to Evaluate the Safety and Tolerability of Tezepelumab in Adults and Adolescents with Severe Uncontrolled Asthma (DESTINATION) | AstraZeneca | Ongoing | Tezepelumab | 3 | D5180C00018 | KAUH-J |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Cardiovascular Outcomes Following Treatment With Alogliptin in Addition to Standard of Care in Subjects With Type 2 Diabetes and Acute Coronary Syndrome | Takeda | Rejected | Alogliptin | 3 | SYR-322_402 | PSMMC |
| A Multicenter, Open-label, Single-arm, Expanded Access Protocol of AMG 510 (pINN Sotorasib) for the Treatment of Subjects with Previously Treated Locally Advanced Unresectable/Metastatic NSCLC with KRAS p.G12C Mutation | Amgen | Ongoing | AMG 510 (Sotorasib) | 3 | 20190436 | King Fahad Specialist Hospital (Dammam) |
| A Multicenter, Open-label, Single-arm Study of a Pertuzumab in Combination With Trastuzumab and a Taxane in First Line Treatment of Patients With HER2- Positive Advanced (Metastatic or Locally Recurrent) Breast Cancer | Roche | Completed | Pertuzumab + Trastuzumab +Taxane | 3 | MO28047 | KFSH & RC-R |
Last update date: 08/05/2025 at 03:17 PM Saudi Arabia time
No feedback has been submitted for this page yet.
Comments and Suggestions
For any inquiries or comments about the government services, please fill in the required information.